Sugi Predict

Sugi Predict / Compounds / SCHEMBL1719399

SCHEMBL1719399

SCHEMBL1719399

O=C(Cl)CCC(=O)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.63
▸ MAPK1 P28482 2/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ KMT2A Q03164 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ TDP1 Q9NUW8 3/20 0.52
▸ SLC6A2 P23975 1/20 0.52
▸ SLC6A3 Q01959 1/20 0.52
▸ LMNA P02545 3/20 0.50
▸ NOTUM Q6P988 1/20 0.50
▸ HCAR2 Q8TDS4 1/20 0.47
▸ CDC25B P30305 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ EPHX2 P34913 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177836 0.90 ALDH1A1 (0.73) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL11343298 0.89 ALDH1A1 (0.59) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL4251494 0.89 ALDH1A1 (0.59) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL16640264 0.88 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL27003867 0.88 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL11385884 0.88 ALDH1A1 (0.58) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL31665250 0.86 ALDH1A1 (0.56) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL5989538 0.86 ALDH1A1 (0.70) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL3730231 0.85 ALDH1A1 (0.61) ALDH1A1MAPK1L3MBTL1KMT2AMEN1
SCHEMBL1856208 0.85 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107011203-B A kind of preparation method of LCZ696 intermediate A HU-377 江苏阿尔法药业有限公司 2019-03-29 — — CN claimed
WO-2024169071-A1 METHOD FOR PREPARING SACUBITRIL COMPOUND BY MEANS OF ASYMMETRIC CATALYTIC HYDROGENATION 瑞博(苏州)制药有限公司 2024-08-22 — — WO disclosed
CN-116368146-A Novel ligands for asialoglycoprotein receptors 赛诺菲 2023-06-30 — — CN disclosed
US-20230203474-A1 COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2023-06-29 — — US disclosed
CN-115974634-A Method for preparing Shakubatu compound by asymmetric catalytic hydrogenation 瑞博(苏州)制药有限公司 2023-04-18 — — CN disclosed
EP-3233889-B1 ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) 2022-07-06 — — EP disclosed
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2020-02-18 — — US disclosed
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF BIOTHERYX, INC. 2019-09-12 — — US disclosed
CN-107011203-B A kind of preparation method of LCZ696 intermediate A HU-377 江苏阿尔法药业有限公司 2019-03-29 — — CN disclosed
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof BIOTHERYX, INC. (US) 2018-12-04 — — US disclosed
CN-1206712-A Heterocyclic compound, preparation process thereof and medicinal composition containing same ADIR (FR) 1999-02-03 — — CN disclosed
EP-0815103-A1 TRYPSIN AND THROMBIN INHIBITORS Novartis AG (CH) 1998-01-07 — — EP disclosed
EP-0458207-B1 Indole derivatives FUJISAWA PHARMACEUTICAL CO (JP) 1997-03-26 — — EP disclosed
WO-1996029327-A1 TRYPSIN AND THROMBIN INHIBITORS NOVARTIS AG (CH) 1996-09-26 — — WO disclosed
US-5312829-A Testosterone 5alpha-reductase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-05-17 — — US disclosed
US-5212320-A Enzyme inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-05-18 — — US disclosed
EP-0458207-A2 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-27 — — EP disclosed
US-4820852-A Process for the preparation of diacyl-dianhydro hexitols CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA (HU) 1989-04-11 — — US disclosed
EP-0034700-A1 Salts of erythromycin A esters and preparation process ABBOTT LABORATORIES (US) 1981-09-02 — — EP disclosed
US-4264765-A ANTIBIOTICS ABBOTT LABORATORIES (US) 1981-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10144745-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B ALDH1A1 1357/4885MAPK1 890/4885L3MBTL1 2063/4885
US-20230203474-A1 COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID SNRPA, NSUN2, POLRMT ALDH1A1 2601/4885MAPK1 3521/4885L3MBTL1 563/4885
US-10562917-B2 Chimeric compounds targeting proteins, compositions, methods, and uses thereof IKZF3, IKZF1, CKS1B ALDH1A1 1357/4885MAPK1 890/4885L3MBTL1 2063/4885
US-20190276474-A1 CHIMERIC COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF IKZF3, IKZF1, CKS1B ALDH1A1 1357/4885MAPK1 890/4885L3MBTL1 2063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.